Clinical trials market seen reaching $151.43 billion by 2035

Market Research Future forecasts the global clinical trials market will rise from $84.11 billion in 2025 to $151.43 billion by 2035, driven by oncology demand, regulatory harmonization and decentralized trial models. The outlook points to faster study starts, heavier use of AI and hybrid execution, and continued growth in North America, Europe and Asia-Pacific.

Why it matters: - The clinical trials market underpins how drugs and devices move from development to approval, so faster growth in this sector signals more spending on R&D infrastructure and trial execution. - The forecast to $151.43 billion by 2035 suggests sponsors will keep investing in oncology, rare disease and technology-enabled studies to manage rising development complexity. - Regulatory changes and decentralized trial tools are expected to change how quickly studies start and how efficiently sponsors can recruit and retain participants.

What happened: - Market Research Future sized the global clinical trials market at $84.11 billion in 2025. - The firm projects the market will reach $151.43 billion by 2035. - The forecast period runs from 2026 to 2035, with the market opening at $89.25 billion in 2026. - The implied compound annual growth rate is 6.05%.

The details: - Oncology and rare-disease pipelines are expanding, with the FDA authorizing 50 novel therapeutics in 2024 and oncology accounting for roughly a third of approvals. - Large oncology registration programs often exceed $300 million in cumulative study cost. - The EU Clinical Trials Regulation became fully binding through the CTIS portal in January 2025, consolidating 27 national submissions into one dossier for multi-country studies. - The U.S. Inflation Reduction Act is pushing sponsors to compress evidence-generation cycles because of Medicare negotiation timing. - The FDA finalized guidance on decentralized trials in September 2024, giving sponsors clearer rules for remote consent, local labs and direct-to-participant drug shipment. - Venture and corporate investment in trial-technology vendors topped $4.8 billion between 2023 and 2025. - IQVIA Holdings has an estimated 13% to 16% revenue share, supported by its Connected Intelligence platform and real-world data assets. - ICON plc holds about 9% to 12% share after integrating PRA. - Thermo Fisher, through PPD, holds about 8% to 11% share with clinical development, central lab and bioanalytical services. - NIH yearly funding obligations exceed $47 billion, supporting a large investigator base in the U.S. - Phase III is the largest segment, with 51.2% share in 2025. - Phase II is the fastest-growing phase, at 6.32% CAGR. - Phase IV generated $4.12 billion in 2025. - Interventional studies held 67.2% share in 2025. - Observational studies were valued at $20.61 billion in 2025. - Adaptive and other designs are the fastest-growing study design segment, at 7.63% CAGR. - Clinical trial monitoring was the dominant service type, with 26.5% share in 2025. - Site identification and patient recruitment reached $14.97 billion in 2025. - Decentralized services are the fastest-growing service line, at 13.58% CAGR. - Oncology led therapeutic areas with 27.6% share in 2025. - Infectious disease was valued at $10.77 billion in 2025. - Neurology and CNS is the fastest-growing therapeutic area, at 8.46% CAGR. - Pharmaceutical and biopharmaceutical companies were the dominant sponsor group, with 63.2% share in 2025. - Medical device companies accounted for $11.86 billion in 2025. - Government and non-profit sponsors are the fastest-growing group, at 6.98% CAGR. - North America led the market with 45.8% of global revenue in 2025, equal to about $38.52 billion. - Europe was the second-largest region at $20.69 billion in 2025, with a 24.6% share. - Asia-Pacific is the fastest-growing region, at 7.34% CAGR. - South America reached $3.87 billion in 2025. - The Middle East and Africa held about 3.6% of global share.

Between the lines: - The market outlook reflects a shift from basic trial execution toward more complex evidence generation, especially in oncology and precision medicine. - CTIS, ICH E6(R3) and decentralized-trial guidance are reducing administrative friction, which should favor sponsors and CROs that can scale across multiple countries. - AI-assisted site selection and screening are becoming a competitive advantage because they can cut failed site costs and shorten enrollment timelines. - The most attractive vendors are likely to be those that combine data, technology and operational delivery in one platform.

What's next: - Sponsors are expected to expand use of hybrid trial models, AI-enabled feasibility tools and centralized monitoring. - Growth opportunities are likely in Asia-Pacific enrollment networks, biomarker-gated oncology studies and agentic automation for study operations. - Technology-plus-service partnerships may become more common as sponsors look to shorten timelines without sacrificing data quality. - Market leadership will likely favor operators that can improve enrollment while maintaining compliance across decentralized global studies.

The bottom line: - The clinical trials market is on track for steady, long-run expansion as drug development becomes more global, more data-heavy and more dependent on technology.